ETF Worth Mentioning: VanEck Vectors Pharmaceutical ETF (PPH) Declines 0.35% for Nov 23

November 23, 2016 - By Nellie Frank   ·   0 Comments

Nov 23 is a negative day so far for VanEck Vectors Pharmaceutical ETF (NASDAQ:PPH) as the ETF is active during the day after losing 0.35% to hit $51.95 per share. The exchange traded fund has 254.82 million net assets and 1.49% volatility this month.

Over the course of the day 36,128 shares traded hands, as compared to an average volume of 98,800 over the last 30 days for VanEck Vectors Pharmaceutical ETF (NASDAQ:PPH).

The ETF is -16.56% of its 52-Week High and 7.33% of its low, and is currently having ATR of 1.09. This year’s performance is -15.13% while this quarter’s performance is -10.95%.

The ETF’s YTD performance is 0%, the 1 year is 0% and the 3 year is 0%.

More notable recent VanEck Vectors Pharmaceutical ETF (NASDAQ:PPH) news were published by: Businesswire.com which released: “VanEck Announces March 2016 Distribution for Market Vectors Pharmaceutical ETF” on March 31, 2016, also Marketwatch.com with their article: “Generic-drug maker ETF could outperform biotech peers under Clinton” published on November 08, 2016, Businesswire.com published: “Van Eck Announces Primary Listing Venue Change for Two Market Vectors® ETFs” on January 06, 2016. More interesting news about VanEck Vectors Pharmaceutical ETF (NASDAQ:PPH) were released by: Investorplace.com and their article: “The 10 Best Pharma Stocks Under President Donald Trump” published on November 17, 2016 as well as Zacks.com‘s news article titled: “Healthcare ETFs in the Spotlight as Election Approaches” with publication date: November 07, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>